Xofigo Radium-223 en Israël — obtenez 3 cliniques correspondantes avec les coûts

Xofigo Radium-223 side effects include nausea, diarrhea, and fatigue, as the alpha-particle medication targets bone metastases. Common hematological responses include temporary drops in red blood cell counts. Israeli oncology centers like Sourasky Medical Center manage these effects through specialized intravenous infusion protocols and supportive care.

• Gastrointestinal response: Nausea and loss of appetite typically occur during the first week after injection.
• Hematological monitoring: Blood work may show temporary red blood cell fluctuations a few weeks post-treatment.
• Physical energy: Fatigue is frequently reported in the immediate period following the intravenous infusion.
• Oral health: Dry mouth (Xerostomia) is a principal adverse effect and can sometimes become irreversible.

Bookimed Expert Insight: While Xofigo primarily causes fatigue, many patients accidentally confuse its side effects with thyroid-related radioactive iodine therapy. Top Israeli specialists like Dr. Ofer Merimsky emphasize aggressive hydration specifically to mitigate oral side effects, a detail often overlooked in standard oncology consultations.

Patient Consensus: Many patients emphasize the need for regular blood monitoring to track cell counts. People frequently recommend aggressive hydration to manage dry mouth symptoms effectively after each injection.

Xofigo causes bone marrow suppression because the radioactive Radium-223 isotope mimics calcium, targeting bone metastases near blood-cell-producing tissue. While most patients experience temporary drops in red blood cells or platelets, 2% may face serious bone marrow failure requiring close hematologic monitoring.

• Affected cells: Treatment lowers counts of red cells, white cells, and platelets.
• Monitoring protocol: Israeli oncology centers perform blood tests before each of the 6 injections.
• Recovery timeline: Blood cell levels typically recover naturally within several weeks post-treatment.
• Severe risks: Clinical data shows a 2% risk of fatal bone marrow failure.

Bookimed Expert Insight: Israeli centers like Sourasky manage these risks by leveraging EBMT-certified hematology standards. While Xofigo costs $7,800 to $10,500 here, the true value lies in specialized monitoring. Professor Ofer Merimsky at Sourasky coordinates care to identify count drops early, maintaining a safer profile compared to standard radiotherapy.

Patient Consensus: Most patients report mild fatigue and occasional bruising but find the blood count drops are temporary. Many emphasize that this hematologic impact resolves much easier than the permanent side effects of other radiation therapies.

Radiation safety protocols for Xofigo Radium-223 focus on managing internal alpha-emitter isotopes. Patients must minimize contact with biological waste for several days following injection. While alpha radiation travels short distances, strict hygiene prevents accidental ingestion by family members within JCI-accredited facilities in Israel.

• Hygiene protocol: Flush toilets twice after use to clear biological waste safely.
• Personal contact: Limit close contact with children and pregnant women for 3–7 days.
• Waste management: Wash hands thoroughly after urination to prevent internalizing radioactive materials.
• Sleeping arrangements: Use a separate bed for 3–5 nights to minimize proximity.

Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center manage 40,000 cancer patients yearly with high efficiency. For Xofigo therapy, the cost ranges from $7,800 to $10,500, which is a significant saving of 90% compared to the US average of $90,000. These savings often cover extra nights in local accommodations, which simplifies following the 5-day isolation period before traveling home.

Patient Consensus: Accuracy in hygiene is vital since radiation risks are internal rather than external. Patients recommend requesting a specific safety brochure from your oncologist to navigate home-care protocols confidently.

Xofigo (Radium-223) is a targeted radioactive treatment for men with castration-resistant prostate cancer that has spread to the bones. This alpha-emitting radiopharmaceutical mimics calcium to target bone metastases, delivering localized radiation that destroys cancer cells while sparing surrounding healthy tissue and critical organs.

• Targeted indication: Used for symptomatic bone metastases without known visceral spread to organs.
• Treatment mechanism: Acts as a calcium analog to deliver short-range alpha radiation to tumors.
• Standard protocol: Administered via intravenous infusion every 4 weeks for 6 total sessions.
• Clinical benefits: Designed to extend survival and significantly reduce cancer-related bone pain.

Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center (Ichilov) serve 40,000 cancer patients annually. This volume is critical because Xofigo requires precise nuclear medicine handling. If cancer spreads beyond the bones, Israeli specialists often pivot to Lutetium-177 (Pluvicto) as a more effective systemic alternative.

Patient Consensus: Patients emphasize that Xofigo is most effective when bone pain is the primary symptom. While some see immediate relief, others suggest discussing Lutetium-177 if imaging shows the disease moving into the liver or lungs.

Candidates for Xofigo in Israel include adult men with metastatic castration-resistant prostate cancer experiencing symptomatic bone metastases. These patients typically exhibit disease progression despite hormonal therapy and have no known visceral metastases in the lungs or liver, confirmed via PSMA PET/CT scans at centers like Sourasky.

• Cancer stage: Confirmed castration-resistant prostate cancer showing progression despite therapy.
• Metastatic status: Documented symptomatic spread specifically to the bone structure.
• Exclusion criteria: Absence of significant visceral involvement in internal organs.
• Facility standard: Joint Commission International accredited hospitals managing 40,000+ oncology patients.

Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center offer Xofigo at $7,800 to $10,500, which is 90% less than the $90,000 American average. This cost difference allows patients to access advanced diagnostics like Novalis TrueBeam STx and Foundation One CDx testing within the same therapeutic budget.

Patient Consensus: Patients emphasize verifying bone-only status through imaging before arrival to ensure eligibility. Most describe the outpatient infusion as manageable with significantly fewer side effects than traditional chemotherapy regimens.

Xofigo can be combined with hormone therapies like LHRH analogues and enzalutamide to treat prostate cancer. However, it must not be used with abiraterone acetate or chemotherapy. These combinations significantly increase the risk of fractures, bone marrow suppression, and mortality.

• Safe combinations: Clinics use Xofigo alongside hormone therapies like LHRH analogues or enzalutamide safely.
• High-risk pairings: Doctors strictly avoid abiraterone (Zytiga) to prevent fatal bone fractures and death.
• Sequential therapy: Specialists like Dr. Ofer Merimsky may sequence Xofigo with Lutetium-177 radioligand therapy.
• Local integration: Stereotactic body radiation therapy (SBRT) often manages specific painful lesions during systemic treatment.

Bookimed Expert Insight: While global guidelines allow enzalutamide, Israeli oncologists at Sourasky Medical Center prioritize marrow health. They often reserve Xofigo as a third-line therapy. This strategy preserves bone marrow function for secondary treatments like Lutetium-177. Patients with existing marrow issues may be ineligible for combining these powerful radiopharmaceuticals.

Patient Consensus: Patients emphasize verifying bone marrow status before starting. Many view Xofigo primarily as a tool for managing bone pain and improving daily quality of life.

Xofigo works by mimicking calcium to deliver targeted alpha-particle radiation directly to bone metastases. This therapy treats castration-resistant prostate cancer that has spread to bones. It destroys tumor DNA within a short range, preserving surrounding healthy tissue and bone marrow.

• Targeting mechanism: Radium-223 mimics calcium to seek out areas of high bone turnover.
• Radiation type: Alpha particles deliver high energy across just 10 cell diameters.
• Treatment cycle: Patients receive 6 intravenous injections spaced exactly 1 month apart.
• Pain management: Most patients report noticeable relief after their second or third injection.

Bookimed Expert Insight: While Xofigo targets bone lesions, Israeli oncology centers like Sourasky Medical Center often combine it with genetic testing like Foundation One CDx. This dual approach ensures the treatment matches the specific tumor profile. This is crucial because Xofigo only treats bone-specific spread, not soft-tissue metastases.

Patient Consensus: Patients should prepare for gradual improvements rather than instant results after the first dose. Common feedback highlights managing extreme fatigue and appetite changes during the 6-month course.